CytomX’s Approach To Antibody-Drug Conjugates Earns Deal With Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held California biotech calls its ADC technology Probody Drug Conjugates and claims it can create antibodies that will activate in a tumor’s micro-environment, while remaining dormant in healthy tissue. Pfizer is paying $25 million divided between upfront cash and preclinical milestones for a licensing deal around CytomX’s Probody Platform technology.